|1.||Cummings, Jeffrey: 3 articles (05/2006 - 02/2002)|
|2.||Ethell, Brian T: 2 articles (05/2006 - 02/2002)|
|3.||Burchell, Brian: 2 articles (05/2006 - 02/2002)|
|4.||Smyth, John F: 2 articles (01/2004 - 02/2002)|
|5.||Jodrell, Duncan I: 2 articles (01/2004 - 02/2002)|
|6.||Boyd, Gary: 2 articles (01/2004 - 02/2002)|
|7.||Jardine, Lesley: 1 article (05/2006)|
|8.||Maliepaard, Mark: 1 article (01/2004)|
|9.||Allen, John D: 1 article (01/2004)|
|10.||Yao, Denggao: 1 article (01/2004)|
|1.||Colonic Neoplasms (Colon Cancer)
01/01/2004 - "In drug accumulation studies in human colon cancer cell lines NU/ICRF 505 was taken up avidly and retained in cells lacking UGTs (HCT116), whereas, following equally rapid uptake, it was cleared rapidly from cells displaying UGT activity (HT29) as glucuronide metabolites. "
07/01/1996 - "NU/ICRF 505 was rapidly metabolized in nude mice to a product which represented the sole detectable form of the drug present in plasma and a chemosensitive human xenograft (HT-29 colon cancer). "
05/01/2006 - "LC-MS was applied to measure rates of glucuronidation of two anticancer compounds (SN-38 and NU/ICRF 505) by patient colon cancer biopsies and paired normal colon. "
05/01/2006 - "Glucuronidation of SN-38 and NU/ICRF 505 in human colon cancer and adjacent normal colon."
10/11/1996 - "In addition, NU/ICRF 505 significantly inhibited the growth of two human xenografts (HT-29 colon cancer and NX002 nonsmall-cell lung cancer) in nude mice after i.p. "
08/01/1996 - "Subsequent studies with the human lung (NX002), ovarian (A2780) and colon (HT29) cancer cell lines yielded evidence of formation of higher molecular weight DNA fragments in NX002 and A2780 cells in response to NU/ICRF 505 (5 microM). "
08/01/1996 - "Induction of apoptosis in human cancer cell lines by the novel anthracenyl-amino acid topoisomerase I inhibitor NU/ICRF 505."
|3.||Colorectal Neoplasms (Colorectal Cancer)
02/15/2002 - "As part of a program to identify novel mechanisms of resistance to topoisomerase I (topo I) inhibitors, the cellular pharmacology of 7-ethyl-10-hydroxycamptothecin (SN-38), the active metabolite of clinically used irinotecan (CPT-11) and NU/ICRF 505, an anthraquinone-tyrosine conjugate, has been investigated in two human colorectal cancer (CRC) cell lines. "
|4.||Lung Neoplasms (Lung Cancer)
|5.||Breast Neoplasms (Breast Cancer)
|1.||DNA (Deoxyribonucleic Acid)
|3.||Type I DNA Topoisomerases (Topoisomerase I)
|4.||Topoisomerase I Inhibitors
|5.||Uridine Diphosphate (UDP)
|8.||Carrier Proteins (Binding Protein)
|10.||trioctyl phosphine oxide (TOPO)
|1.||Heterologous Transplantation (Xenotransplantation)